1206.5000 28.90 (2.45%)
NSE May 07, 2026 15:31 PM
Volume: 2.5M
 

Ashika Research
The company operates in 4 segments: Generics APIs, Generics FDFs, Synthesis and Ingredients. Generics API business comprises the development, manufacture and sale of APIs and advanced intermediates; Generics FDF business comprises the development and manufacture of oral solid formulations; Synthesis business includes contract development and manufacturing services for global pharmaceutical companies; and Ingredients business comprises the manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors....
Number of FII/FPI investors increased from 421 to 429 in Mar 2026 qtr.
More from Laurus Labs Ltd.
Recommended